# Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

> **NCT05082415** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9456 (actual)

## Conditions studied

- Age-related Macular Degeneration (AMD)

## Interventions

- **DRUG:** Brolucizumab

## Key facts

- **NCT ID:** NCT05082415
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-03
- **Primary completion:** 2020-12-15
- **Final completion:** 2020-12-15
- **Target enrollment:** 9456 (ACTUAL)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082415, "Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05082415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*